Established Efficacy in Patients with SLE
BENLYSTA IS THE FIRST BIOLOGIC APPROVED TO TREAT CLINICAL MANIFESTATIONS OF SLE WHEN ADDED TO STANDARD THERAPY
Superior disease activity reduction (SRI-4) vs standard therapy (ST) alone at Week 521-3
Primary endpoint

SRI-4 achieved significant improvement
These reductions were primarily related to improvements in the mucocutaneous, musculoskeletal, and immunologic organ domains.
SRI = SLE Responder Index; SC = subcutaneous.
* In BLISS-76, the difference in SRI-4 response rates was not significantly different at Week 76 (secondary endpoint).

There were no statistically significant differences between treatment groups in any trial.
†† In patients who were receiving >7.5 mg/day at baseline. Overall, 60%, 69%, and 46% of patients were receiving doses >7.5 mg/day at baseline in BLISS-SC, BLISS-52, and BLISS-76, respectively.
‡‡ In BLISS-SC, BLISS-52, and BLISS-76, this was a secondary endpoint.